Posted by Michael Wonder on 05 Jul 2022
Health Canada approves the use of Cibinqo (abrocitinib) for the treatment of patients 12 years of age and older with moderate-to-severe atopic dermatitis
4 July 2022 - Pfizer Canada announces today that Health Canada has approved Cibinqo (abrocitinib) for the treatment of patients 12 years and older with refractory moderate to severe atopic dermatitis, including the relief of pruritus, who have had an inadequate response to other systemic drugs, (e.g. steroid or biologic), or for whom these treatments are not advisable.
Cibinqo can be used with or without medicated topical therapies for atopic dermatitis.
